Inequality in survival of people with head and neck cancer: Head and Neck 5000 cohort study by Ingarfield, Kate et al.
OR I G I N A L AR T I C L E
Inequality in survival of people with head
and neck cancer: Head and Neck 5000 cohort study
Kate Ingarfield BSc1,2,3 | Alex D. McMahon PhD1 | Katrina Hurley BSc3 |
Stu Toms3 | Miranda Pring PhD3 | Steve J. Thomas PhD3 |
Andrea Waylen PhD4 | Michael Pawlita MD5 | Tim Waterboer PhD5 |
Andy R. Ness PhD3 | David I. Conway PhD1
1School of Medicine, Dentistry, and
Nursing, University of Glasgow,
Glasgow, UK
2Centre for Trials Research, College of
Biomedical and Life Science, Cardiff
University, Cardiff, UK
3National Institute for Health Research
(NIHR) Bristol Biomedical Research
Centre, University Hospitals Bristol NHS
Foundation Trust and University of
Bristol, Bristol, UK
4Bristol Dental School, University of
Bristol, Bristol, UK
5Infections and Cancer Epidemiology,
German Cancer Research Center (DKFZ),
Heidelberg, Germany
Correspondence
Kate Ingarfield, School of Medicine,
Dentistry, and Nursing, University of




Above and Beyond, University Hospitals
Bristol Research Capability Funding;
Cancer Research UK Programme Grant,
the Integrative Cancer Epidemiology
Programme, Grant/Award Number:
C18281/A19169; National Institute for
Health Research (NIHR) under its
Programme Grants for Applied Research
Scheme, Grant/Award Number: RP-PG-
0707-10034; NHS National Services
Scotland (NSS) PhD Studentship
Abstract
Background: Explanations for socioeconomic inequalities in survival of head
and neck cancer (HNC) patients have had limited attention and are not well
understood.
Methods: The UK Head and Neck 5000 prospective clinical cohort study was
analyzed. Survival relating to measures of socioeconomic status was explored
including area-based and individual factors. Three-year overall survival was
determined using the Kaplan–Meier method. All-cause mortality was investi-
gated via adjusted Cox Proportional Hazard models.
Results: A total of 3440 people were included. Three-year overall survival was
76.3% (95% CI 74.9, 77.7). Inequality in survival by deprivation category,
highest education level, and financial concerns was explained by age, sex,
health, and behavioral factors. None of the potential explanatory factors fully
explained the inequality associated with annual household income or the pro-
portion of income of benefits.
Conclusion: These results support the interventions to address the financial
issues within the wider care and support provided to HNC patients.
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1 | INTRODUCTION
Inequality in survival of people with cancer is well docu-
mented both globally1-5 and in the United Kingdom
(UK).6-8 Many studies highlight that people with cancer
who are from disadvantaged socioeconomic backgrounds
experience worse outcomes than those from more affluent
backgrounds.1-8 Potential explanations for inequality differ
between studies and remain unclear. However, explana-
tions for inequality in survival of people with cancer are
an important and unsolved issue in medical research.
Possible explanations for inequality in survival of peo-
ple with head and neck cancer (HNC) include sugges-
tions that participants who were at a socioeconomic
disadvantage presented with cancers at a more advanced
stage, or that they presented more frequently with addi-
tional comorbidities.3,9-11 However, results from other
studies have reported conflicting findings.12 Previous
work from a cohort of people in Scotland suggested that
inequality in survival of people with HNC can be
explained by a combination of demographics, tumor and
treatment factors.13
At present, HNC accounts for nearly 900 000 cases
and more than 450 000 deaths per year throughout the
world.14 There were nearly 12 000 new cases of HNC and
more than 4000 deaths attributable to the disease in the
UK in 2016.15 The main risk factors of HNC are smoking
and alcohol consumption,16,17 and in recent years, the
human papillomavirus (HPV) has shown to be associated
with the rising incidence of oropharyngeal cancer.18 Low
socioeconomic position is an additional and independent
risk factor of HNC and inequality in incidence of HNC
has been observed between and within developed and
developing countries.19-21
Other studies have relied on either area-based or indi-
vidual measures of socioeconomic status (SES) to docu-
ment and explain potential explanatory factors of
inequality in survival of people with cancer. No prior
study has investigated both forms of measurements of
SES. This study aims to undertake an in-depth explora-
tion into the nature and extent of inequality in survival of
people with HNC by considering area-based and individ-
ual dimensions of socioeconomic circumstances and, in
addition, to understand the underlying cause of this
inequality.
2 | MATERIALS AND METHODS
2.1 | Data collection
HN5000 is a prospective clinical cohort study of people
with HNC. The study has been described in detail
elsewhere.22,23 Briefly, people with a new diagnosis of
HNC in England, Wales and Scotland, were recruited to
the study between April 5, 2011 and December 31, 2014.
Information was gathered from clinical records using
data capture forms which were completed by research
staff on participants' diagnoses and treatment modality.
In addition, participants were asked to complete three
questionnaires at baseline prior to the start of treatment,
at 4 months after diagnosis, and at 12 months after diag-
nosis. At each time point, the participants were asked
about their demographics, health, behaviors and a variety
of information about their socioeconomic position
(described in detail later). In addition, there were also
separate questionnaire sheets enquiring about the partici-
pants' outlook and feelings at each time point, and about
their sexual behavior history at baseline. Full ethical
approval was granted by the National Research Ethics
Committee (South West Frenchay Ethics Committee, ref-
erence 10/H0107/57, November 5, 2010) and it was
approved by the Research and Development departments
for the participating NHS trusts.
2.2 | SES variables
2.2.1 | Area-based measurement of SES
The area-based measurement of SES was derived from
English Index of Multiple Deprivation (IMD) 2010
scores24 which were linked to HN5000 using the partici-
pants' home postcodes and Lower Layer Super Output
Area codes.25 IMD 2010 categorizes geographical areas in
England using information from seven domains includ-
ing: Income Deprivation; Employment Deprivation;
Health Deprivation and Disability; Education Skills and
Training Deprivation; Barriers to Housing and Services;
Living Environment Deprivation and Crime. The IMD
2010 score has five categories—group 1 represents the
most deprived areas and group 5 represents the least
deprived areas.
2.2.2 | Individual measurements of SES
Individual measurements of SES were obtained from par-
ticipants' questionnaire responses at baseline before treat-
ment started. This included: highest education level
attained, number of years in full-time education, total
annual household income, proportion of income from
benefits, and financial concerns of living with or after
cancer. The highest education level that the participants
had attained was grouped as: (a) up to secondary school
(primary school or secondary school, usually including
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students up to the age of 16), (b) further education
(school/college sixth form or further education college,
usually including students between the ages of 16 to 18),
or (c) higher education or university (university or poly-
technic university, usually including students aged
18 and over). The number of years spent in education
was categorized as: (a) 10 years or less, (b) 11 to 13 years,
or (c) 14 years or more, and the total annual household
income of the participants was grouped as: (a) less than
£11 999 a year, (b) between £12 000 (approximately
18 826 US$ in August 2012) and £28 999 a year, or
(c) more than £29 000 a year (approximately 45 497 US$
in August 2012). Note that in the financial year
2012/2013 the median disposable income in the UK was
approximately £24 200. The total proportion of a partici-
pant's income received from benefits was recorded on the
questionnaire as: (a) all, (b) about three quarters,
(c) about half, (d) about a quarter, (e) very little, or (f)
none, but for the purpose of this analysis, this was
grouped as: (a) all, (b) some (groups b to e), or (c) none.
Whether the participants had any financial concerns of
living with or after cancer or not was recorded as: (a) yes,
or (b) no.
2.3 | Potential explanatory factors
2.3.1 | Demographic data
Participants' age at the date of consent and their sex were
recorded on data capture forms. Marital status was
recorded on the baseline questionnaire as: (a) single,
(b) widowed, (c) separated, (d) married, (e) divorced, or
(f) living with a partner, and for the purpose of this anal-
ysis, this was grouped as: (a) single; (b) married or living
with a partner; or (c) separated, divorced or widowed.
2.3.2 | Health status
Health status was recorded via comorbidity and World
Health Organization (WHO) Performance Status26 from
baseline data before treatment started. Comorbidity was
recorded on the baseline data capture form using the
Adult Comorbidity Evaluation (ACE-27),27 which catego-
rizes participants as having: (a) no comorbidity, (b) mild
comorbidity, (c) moderate comorbidity, or (d) severe
comorbidity—for the purpose of this analysis the worst
two comorbidities were grouped into a “moderate/
severe” category. WHO Performance Status was mea-
sured on the participants' baseline questionnaire and
recorded as: (a) normal activity, (b) strenuous activity
restricted, (c) up and about for more than 50% of their
waking hours, (d) confined to a bed or chair for more
than 50%, or (e) confined to a bed or chair for 100% of
their waking hours. Due to small numbers, the worst two
WHO Performance Status categories were combined into
a “confined to a bed or chair for more than 50% of their
waking hours” category.
2.3.3 | Behavioral factors
Participants' behavioral data were recorded on smoking
status and alcohol consumption. Smoking status was
recorded on the baseline questionnaire and was defined
as: (a) current smoker, (b) previous smoker, or (c) never
smoked, where smoking was defined as having smoked
at least one cigarette during a whole year. The number of
units of alcohol per week that the participants drank was
calculated from baseline questionnaire responses to:
(a) how many days per week they drank alcohol; and
(b) how many bottles of wine, spirits, or pints of beers/
lager/cider they drank each week before they were diag-
nosed with cancer. Using these responses, participants'
alcohol consumption was calculated in units and was
subsequently grouped as: (a) none, (b) moderate (more
than zero and less than 14 units per week for men and
women), (c) hazardous (between 14 and 50 units per
week for men, and between 14 and 35 units per week for
women), or (d) harmful (more than 50 units per week for
men, and more than 35 units per week for women).28
2.3.4 | Tumor and treatment factors
Tumor and treatment factors included information on
the anatomical site of the tumor, tumor stage, HPV sta-
tus, and treatment modality. Anatomical site was deter-
mined using the International Classification of Diseases
Version 10 (ICD-10).29 Tumors of the lip and oral cavity
(C00, C02-C06), oropharynx (C01, C05.1, 2, C09.0, 1, 9,
C10.0, 2, 3), nasopharynx (C11), hypopharynx (C12,
C13), larynx (C32.0, 1, 2, C10.1), nasal cavity (C30.0),
sinuses (C31.0, 1), major salivary glands (C07, C08),
minor salivary glands (any ICD-10 code with histology
recorded as “salivary gland”), and other sites of the head
and neck (C14.0, C30.1, C41.1, C69.5) were included.
Due to small numbers, participants with cancers of the
nasopharynx, nasal cavity, sinuses, and other sites of the
head and neck were combined into one group and
labeled as “Other.” Tumor stage was classified using the
tumor, node and metastases (TNM) Classification of
Malignant Tumors from the International Union Against
Cancer (UICC), Seventh Edition, which divides tumors
into four categories from stage I to stage IV.30 HPV status
1254 INGARFIELD ET AL.
was determined by the German Cancer Research Center
(DKFZ) in Heidelberg. An HPV-positive result was deter-
mined from a serological response to HPV16 E6 anti-
bodies using a glutathione S-transferase multiplex assay,
with a cut-off value of more than 1000 Median Fluores-
cence Intensity units.31 Participants' treatment modality
was extracted from data capture forms at four-months
and grouped as: (a) surgery only; (b) chemoradiotherapy
only; (c) radiotherapy only; (d) surgery combined with
chemotherapy, chemoradiotherapy or radiotherapy;
(e) chemotherapy only; or (f) no treatment.
2.4 | Mortality linkage
On October 11, 2018, the cohort was linked to the
National Office of Statistics from the UK Health and
Social Care Information Centre. The number of days
between the date of consent and the date of death or the
most recent follow-up period were calculated.
2.5 | Exclusion criteria
Participants were excluded from the HN5000 if they:
(a) had withdrawn, or (b) were found to be ineligible
because a biopsy result confirmed that they did not have
HNC. For this analysis, we also excluded people who had
a carcinoma in situ, a cancer of stage 0, thyroid cancer,
cancer of unknown primary (CUP), did not live in
England (and therefore could not be linked to IMD data),
and those who did not return their baseline
questionnaire pack.
2.6 | Statistical analyses
All statistical analyses were performed using Stata Ver-
sion 16.32 Numbers and proportions of deaths were dis-
played for each of the participant, demographic, health,
behavioral, tumor, treatment, and SES factors. SES fac-
tors were cross-tabulated with each participant, demo-
graphic, health, behavioral, tumor, and treatment factors.
Three-year survival was determined using the Kaplan–
Meier method and tests for the differences between the
results were determined using the log-rank test. Adjusted
Cox Proportional Hazard models for all-cause mortality
were displayed to identify the potential explanatory fac-
tors of the inequality in survival. Hazard ratios (HRs)
with 95% confidence intervals (CIs) and p-values for each
SES variable were produced to measure the differences in
all-cause mortality. Models were adjusted by: (a) age and
sex; (b) age, sex, and each individual factor separately
including comorbidity, smoking status, alcohol consump-
tion, anatomical site, stage, HPV status, and treatment
modality; (c) age, sex, and health and behavioral factors
combined including comorbidity, smoking status, and
alcohol consumption; (d) age, sex, tumor, and treatment
factors combined including anatomical site, stage, HPV
status, and treatment modality; and (e) age, sex, and all
potential explanatory factors combined including comor-
bidity, smoking status, alcohol consumption, anatomical
site, stage, HPV status, and treatment modality.
2.7 | Multiple imputation
The impact of missing data on the adjusted Cox Propor-
tional Hazard models was explored for each potential
explanatory and SES variable and multiple imputation
(MI) was performed to impute values for missing data.33
The ICE package for the MI of chained equations in Stata
16 was used.34 Twenty imputed datasets were generated
using a model which included the event indicator for
death, the Nelson–Aalen estimator of the cumulative
hazard,35 all SES variables and all potential explanatory
factors. The results of the Cox Proportional Hazard
models following MI were computed using the mim com-
mand in Stata 16,36 which combines the results from
each imputed dataset using Rubin's Rules, incorporating




A total of 5511 participants were recruited to HN5000;
however, 107 (1.9%) participants were excluded from the
cohort due to either withdrawing, being ineligible due to
not having an HNC primary, not consenting to the study,
or having a tumor of stage 0 (Figure 1). In addition, a
total of 1964 (36.3%) participants were excluded from this
analysis due to having thyroid cancer, CUP, residing in
Scotland or Wales, or not returning their baseline ques-
tionnaire pack. Thus, a total of 3440 were eligible for this
analysis—62.4% of the original 5511 people that were
recruited.
3.2 | Missing data
Some data were missing for several potential explanatory
variables which ranged from 0.9% for tumor stage to
15.0% for total annual household income (Tables 1 and
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2). Data were complete for age at date of consent, sex,
anatomical site and treatment modality.
3.3 | Descriptive statistics
3.3.1 | Potential explanatory factors
The number of participants for each demographic,
health, behavioral, tumor, and treatment factor are dis-
played in Table 1. Participants' age at date of consent
ranged from 22 to 95 (median = 62 years). Nearly three
quarters (n = 2526/73.4%) of the cohort were male. More
than a half (n = 1881/54.7%) of the participants had at
least a mild comorbidity; however, 52.3% (n = 1799) of
the cohort were of normal WHO Performance Status.
Approximately, three quarters (n = 2527/73.5%) of the
cohort were either current or former smokers, and 70.3%
(n = 2418) of the participants were moderate to harmful
drinkers. A proportion of 38.8% (n = 1334) people had
tumors of the oropharynx, while 45.2% (n = 1555) tumors
of the cohort had stage IV tumors, and 61.5% (n = 2114)
of HPV negative tumors. Participants were more likely to
be treated with chemoradiotherapy or a combination of
surgery and chemoradiotherapy (n = 1936/56.2%).
3.3.2 | SES factors
A number of participants for each of the SES factors are
displayed in Table 2. There was an even spread of partici-
pants across the IMD Categories ranging from 17.9%
(n = 616) to 21.7% (n = 746) (Table 2). Nearly half
(n = 1556/45.5%) of the cohort had attained an education
level of up to secondary school, and nearly one third
(n = 1007/29.3%) of participants had spent 10 years or
less in full-time education. More than half
(n = 1988/57.8%) of the cohort earned less than £29 000
per year, one third (n = 1100/32.0%) of the cohort earned
at least some of their income from benefits, and 34.3%
(n = 1181) of people had financial concerns of living with
or after cancer.
3.3.3 | Cross-tabulations of potential
explanatory factors with SES factors
People in the most deprived IMD Category were more
likely to be younger, have worse comorbidities, have
worse WHO Performance Status, and be current smokers
or harmful drinkers (Table S1). The most deprived group
by IMD Category were also more likely to have tumors of
FIGURE 1 Flowchart of eligible cases included
1256 INGARFIELD ET AL.
TABLE 1 Frequency, number of people who had died by October 2018, 3-year survival proportions, and age- and sex-adjusted Cox
proportional hazard models for all demographic, health, behavioral, tumor, treatment, and SES factors
Frequency Died by October 2018
Variable (col. %) (row %)
Whole cohort 3440 1068 (31.1%)
Age group
Less than 44 210 (6.1%) 37 (17.6%)
45 to 54 676 (19.7%) 156 (23.1%)
55 to 64 1192 (34.7%) 356 (29.9%)
65 to 74 940 (27.3%) 313 (33.3%)
75 and over 422 (12.3%) 206 (48.8%)
Sex
Male 2526 (73.4%) 820 (32.5%)
Female 914 (26.6%) 248 (27.1%)
Marital status
Single 427 (12.4%) 153 (35.8%)
Separated/divorced/widowed 686 (19.9%) 280 (40.8%)
Married/living with partner 2283 (66.4%) 620 (27.2%)
Unknown 44 (1.3%) 15 (34.1%)
Comorbidity
No comorbidity 1484 (43.1%) 321 (21.6%)
Mild comorbidity 1149 (33.4%) 372 (32.4%)
Moderate/severe comorbidity 732 (21.3%) 352 (48.1%)
Unknown 75 (2.2%) 23 (30.7%)
WHO performance status
Normal activity 1799 (52.3%) 377 (21.0%)
Strenuous activity restricted 843 (24.5%) 306 (36.3%)
Up and about >50% 470 (13.7%) 207 (44.0%)
Confined >50% or 100% 166 (4.8%) 105 (63.3%)
Unknown 162 (4.7%) 73 (45.1%)
Smoking status
Current smoker 664 (19.3%) 301 (45.3%)
Former smoker 1863 (54.2%) 573 (30.8%)
Never smoked 740 (21.5%) 150 (20.3%)
Unknown 173 (5.0%) 44 (25.4%)
Alcohol consumption
Non-drinker 911 (26.5%) 297 (32.6%)
Moderate 729 (21.2%) 179 (24.6%)
Hazardous 1210 (35.2%) 359 (29.7%)
Harmful 479 (13.9%) 182 (38.0%)
Unknown 111 (3.2%) 51 (46.0%)
Anatomical site
Oropharynx 1334 (38.8%) 332 (24.9%)
Lip and oral cavity 900 (26.2%) 318 (35.3%)
Larynx 728 (21.2%) 214 (29.4%)
(Continues)
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TABLE 1 (Continued)
Frequency Died by October 2018
Variable (col. %) (row %)
Hypopharynx 160 (4.7%) 96 (60.0%)
Salivary glands 147 (4.3%) 34 (23.1%)
Other 171 (5.0%) 74 (43.3%)
Stage
I 788 (22.9%) 131 (16.6%)
II 593 (17.2%) 176 (29.7%)
III 473 (13.8%) 155 (32.8%)
IV 1555 (45.2%) 590 (37.9%)
Unknown 31 (0.9%) 16 (51.6%)
HPV status
Negative 2114 (61.5%) 760 (36.0%)
Positive 867 (25.2%) 150 (17.3%)
Unknown 459 (13.3%) 158 (34.4%)
Treatment
Surgery only 765 (22.2%) 167 (21.8%)
Chemoradiotherapy only 1064 (30.9%) 311 (29.2%)
Radiotherapy only 702 (20.4%) 255 (36.3%)
Surgery and chemo/radio 872 (25.3%) 302 (34.6%)
Chemotherapy only 15 (0.4%) 14 (93.3%)
No treatment 22 (0.6%) 19 (86.4%)
IMD category
1—Most deprived 674 (19.6%) 257 (38.1%)
2 616 (17.9%) 188 (30.5%)
3 746 (21.7%) 227 (30.4%)
4 664 (19.3%) 186 (28.0%)
5—Least deprived 655 (19.0%) 182 (27.8%)
Unknown 85 (2.5%) 28 (32.9%)
Highest education level
Up to secondary school 1556 (45.2%) 535 (34.4%)
Further education 827 (24.0%) 229 (27.7%)
Higher education/degree 849 (24.7%) 229 (27.0%)
Unknown 208 (6.0%) 75 (36.1%)
Time in education
10 years or less 1007 (29.3%) 358 (35.6%)
11 to 13 years 1200 (34.9%) 334 (27.8%)
14 years or more 904 (26.3%) 263 (29.1%)
Unknown 329 (9.6%) 113 (34.4%)
Household income
£11 999 or less 884 (25.7%) 344 (38.9%)
£12 000 to £28 999 1104 (32.1%) 336 (30.4%)
£29 000 or more 935 (27.2%) 187 (20.0%)
Unknown 517 (15.0%) 201 (38.9%)
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the larynx, have tumors that were HPV negative, and be
treated with radiotherapy only. People who had attained
an education level of up to secondary school, spent less
than 10 years in full-time education, earned £11 000 per
annum or less, or earned all their income from benefits
were more likely to have worse comorbidities, worse
WHO Performance Status, be current smokers, have can-
cer of the larynx, and have HPV negative tumors
(Tables S2–S5). Participants who had attained an educa-
tion of up to secondary school or remained in full-time
education for 10 years or less were also more likely to be
older (Tables S2 and S3). Participants who earned
£11 999 or less were also more likely to be female and
have stage II tumors. In contrast, people who had speci-
fied that they had financial concerns of living with or
after cancer were more likely to be younger and males
with no comorbidities (Table S6).
3.4 | Overall survival
3.4.1 | Follow-up
The median follow-up time was 4.8 years (IQR = 4.3 to
5.6 years) and 1.6 years (IQR = 0.8 to 2.9 years) for those
who were alive and had died by the end of the follow-up
period, respectively.
3.4.2 | Survival for potential explanatory
factors
Three-year overall survival and age- and sex-adjusted Cox
Proportional Hazard models for all-cause mortality are
displayed in Table 1 for all potential explanatory factors.
Three-year survival for the whole cohort was 76.3% (95%
CI = 74.9% to 777%). People aged 75 and over had the
lowest overall survival at 64.7% (95% CI = 59.9% to
69.0%) compared to those who were younger than
44 who had overall survival of 85.2% (95% CI = 79.7% to
89.4%). Males had lower overall survival than females at
75.5% (95% CI = 73.7% to 77.1%) and 78.8% (95%
CI = 76.0% to 81.3%), respectively. Following the adjust-
ment for age and sex, in both the models prior to and
post MI, participants who were at the highest risk of all-
cause mortality were not married or not living with a
partner, had worse comorbidities, worse WHO Perfor-
mance Status, were current or previous smokers, or were
harmful drinkers. People were also more at risk of all-
cause mortality following age and sex adjustment if they
had tumors of the oral cavity, hypopharynx, or “other”
head and neck sites, had tumors of higher stage, had
HPV negative tumors or were treated with chemotherapy
and/or radiotherapy (with or without surgery).
3.4.3 | Survival for SES factors
Three-year overall survival and age- and sex-adjusted Cox
Proportional Hazard models for all-cause mortality prior
to and post MI are displayed in Table 2 for all the SES
factors. People had worse 3-year overall survival if they
were of the most deprived IMD Category, attained an
education of up to secondary school, or had remained in
education for 10 years or less. People had lower 3-year
survival if they earned less than £11 999 per household or
earned all their income from benefits. Interestingly, there
was no difference in 3-year survival by financial concerns
of living with or after cancer. Following adjustment by
age and sex, both prior to and post MI, participants
remained at a higher risk of all-cause mortality if they
resided in areas of the most deprived IMD Category (pre-
TABLE 1 (Continued)
Frequency Died by October 2018
Variable (col. %) (row %)
Income from benefits
All 487 (14.2%) 213 (43.7%)
Some 613 (17.8%) 231 (27.7%)
None 2126 (61.8%) 548 (25.8%)
Unknown 214 (6.2%) 76 (35.5%)
Financial concerns
Yes 1181 (34.3%) 358 (30.3%)
No 2051 (59.6%) 631 (30.8%)
Unknown 208 (6.0%) 79 (38.0%)
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TABLE 2 Frequency, number of people who had died by October 2018, 3-year survival proportions, and age- and sex-adjusted Cox
proportional hazard models for all demographic, health, behavioral, tumor, treatment, and SES factors
3-year survival
Age- and sex-adjusted prior to
imputation
Age- and sex-adjusted after
imputation
Variable Percent (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Whole cohort 76.3 (74.9, 77.7) - a a a a
Age group <0.001
Less than 44 85.2 (79.7, 89.4) a a a a
45 to 54 82.0 (78.8, 84.7) a a a a
55 to 64 77.8 (75.3, 80.0) a a a a
65 to 74 73.7 (70.8, 76.4) a a a a
75 and over 64.7 (59.9, 69.0) a a a a
Sex 0.006
Male 75.5 (73.7, 77.1) a a a a
Female 78.8 (76.0, 81.3) a a a a
Marital status <0.001
Single 73.8 (69.3, 77.7) 1.58 (1.32, 1.89) <0.001 1.58 (1.32, 1.90) <0.001
Separated/divorced/widowed 67.8 (64.2, 71.1) 1.58 (1.37, 1.83) <0.001 1.60 (1.38, 1.85) <0.001
Married/living with partner 79.5 (77.7, 81.1) 1.00 (Ref.) a 1.00 (Ref) a
Unknown 72.7 (57.0, 83.5) 1.35 (0.81, 2.26) 0.247 a a
Comorbidity <0.001
No comorbidity 83.8 (81.9, 85.6) 1.00 (Ref.) a 1.00 (Ref.) a
Mild comorbidity 75.6 (73.0, 78.0) 1.45 (1.25, 1.70) <0.001 1.45 (1.24, 1.69) <0.001
Moderate/severe comorbidity 62.4 (58.8, 65.8) 2.32 (1.98, 2.71) <0.001 2.29 (1.96, 2.68) <0.001
Unknown 74.7 (63.2, 83.0) 1.43 (0.93, 2.18) 0.100 a a
WHO performance status <0.001
Normal activity 84.1 (82.3, 85.7) 1.00 (Ref.) a 1.00 (Ref.) a
Strenuous activity restricted 72.2 (69.1, 75.1) 1.78 (1.53, 2.07) <0.001 1.77 (1.52, 2.06) <0.001
Up and about >50% 67.5 (63.0, 71.5) 2.30 (1.94, 2.73) <0.001 2.31 (1.95, 2.74) <0.001
Confined >50% or 100% 50.6 (42.8, 57.9) 3.95 (3.18, 4.91) <0.001 3.84 (3.09, 4.79) <0.001
Unknown 64.2 (56.3, 71.0) 2.28 (1.77, 2.94) <0.001 a a
Smoking status <0.001
Current smoker 65.5 (61.8, 69.0) 2.83 (2.32, 3.45) <0.001 2.86 (2.34, 3.49) <0.001
Former smoker 76.6 (74.6, 78.5) 1.56 (1.30, 1.87) <0.001 1.56 (1.31, 1.87) <0.001
Never smoked 84.6 (81.8, 87.0) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 79.8 (73.0, 85.0) 1.27 (0.91, 1.79) 0.157 a a
Alcohol consumption <0.001
Non-drinker 75.9 (72.9, 78.5) 1.00 (Ref.) a 1.00 (Ref.) -
Moderate 81.5 (78.5, 84.1) 0.73 (0.61, 0.88) 0.001 0.75 (0.62, 0.90) 0.002
Hazardous 77.2 (74.7, 79.5) 0.92 (0.79, 1.08) 0.332 0.94 (0.80, 1.10) 0.430
Harmful 69.9 (65.6, 73.8) 1.41 (1.16, 1.70) 0.001 1.41 (1.17, 1.71) <0.001
Unknown 64.9 (55.2, 72.9) 1.53 (1.13, 2.06) 0.005 a a
Anatomical site <0.001
Oropharynx 81.7 (79.5, 83.7) 1.00 (Ref.) a b b
Lip and oral cavity 71.4 (68.4, 74.3) 1.46 (1.24, 1.71) <0.001 b b
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TABLE 2 (Continued)
3-year survival
Age- and sex-adjusted prior to
imputation
Age- and sex-adjusted after
imputation
Variable Percent (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Larynx 79.1 (76.0, 81.9) 0.99 (0.82, 1.18) 0.871 b b
Hypopharynx 48.1 (40.2, 55.6) 2.98 (2.37, 3.75) <0.001 b b
Salivary glands 85.0 (78.2, 89.9) 0.93 (0.65, 1.33) 0.677 b b
Other 67.3 (59.6, 73.7) 1.98 (1.54, 2.55) <0.001 b b
Stage <0.001
I 89.1 (86.7, 91.1) 1.00 (Ref.) a 1.00 (Ref.) -
II 78.9 (75.4, 82.0) 1.93 (1.54, 2.42) <0.001 1.91 (1.53, 2.40) <0.001
III 75.9 (71.8, 79.5) 2.35 (1.86, 2.97) <0.001 2.33 (1.84, 2.94) <0.001
IV 69.3 (67.0, 71.6) 3.01 (2.49, 3.64) <0.001 2.97 (2.45, 3.59) <0.001
Unknown 61.3 (42.0, 75.9) 4.01 (2.39, 6.74) <0.001 a a
HPV status <0.001
Negative 72.2 (70.2, 74.0) 1.00 (Ref.) a 1.00 (Ref.) a
Positive 88.1 (85.8, 90.1) 0.46 (0.38, 0.55) <0.001 0.46 (0.39, 0.55) <0.001
Unknown 73.2 (68.9, 77.0) 0.99 (0.84, 1.18) 0.933 a a
Treatment <0.001
Surgery only 85.2 (82.5, 87.6) 1.00 (Ref.) a b b
Chemoradiotherapy only 77.1 (74.4, 79.5) 1.62 (1.34, 1.97) <0.001 b b
Radiotherapy only 73.2 (69.8, 76.3) 1.65 (1.35, 2.01) <0.001 b b
Surgery and chemo/radio 72.8 (69.7, 75.7) 1.85 (1.53, 2.24) <0.001 b b
Chemotherapy only 13.3 (2.2, 34.6) 11.69 (6.76, 20.22) <0.001 b b
No treatment 13.6 (3.4, 30.9) 17.57 (10.87, 28.39) <0.001 b b
IMD category 0.002
1—Most deprived 71.2 (67.6, 74.5) 1.50 (1.24, 1.81) <0.001 1.49 (1.23, 1.80) <0.001
2 77.9 (74.4, 81.0) 1.13 (0.92, 1.38) 0.007 1.13 (0.92, 1.38) 0.240
3 77.8 (74.6, 80.6) 1.11 (0.91, 1.35) 0.129 1.11 (0.92, 1.35) 0.282
4 77.4 (74.0, 80.4) 0.98 (0.80, 1.20) 0.347 1.11 (0.92, 1.35) 0.816
5—Least deprived 77.3 (73.9, 80.3) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 77.7 (67.2, 85.1) 1.18 (0.79, 1.76) 0.291 a a
Highest education level <0.001
Up to secondary school 74.2 (71.9, 76.3) 1.26 (1.08, 1.47) 0.003 1.26 (1.08, 1.47) 0.003
Further education 77.8 (74.8, 80.4) 1.07 (0.89, 1.29) 0.510 1.07 (0.89, 1.28) 0.496
Higher education/degree 79.4 (76.5, 82.0) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 74.5 (68.0, 79.9) 1.25 (0.96, 1.62) 0.099 a a
Time in education <0.001
10 years or less 73.2 (70.3, 75.8) 1.10 (0.94, 1.29) 0.244 1.10 (0.94, 1.30) 0.229
11 to 13 years 78.9 (76.5, 81.1) 0.97 (0.82, 1.14) 0.676 0.98 (0.83, 1.15) 0.766
14 years or more 76.3 (73.4, 79.0) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 76.6 (71.6, 80.8) 1.19 (0.96, 1.49) 0.116 a a
Household income <0.001
£11 999 or less 70.3 (67.1, 73.1) 2.00 (1.67, 2.40) <0.001 1.92 (1.61, 2.28) <0.001
£12 000 to £28 999 77.6 (75.0, 79.9) 1.47 (1.22, 1.76) <0.001 1.43 (1.20, 1.70) <0.001
(Continues)
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MI HR = 1.50, 95% CI = 1.24 to 1.81; post-MI HR = 1.49,
95% CI = 1.23 to 1.80), or attained an education level of
up to secondary school (pre-MI HR = 1.26, 95% CI = 1.08
to 1.47; post-MI HR = 1.26, 95% CI = 1.08 to 1.47). In
addition, participants were also more at risk of all-cause
mortality after age and sex adjustment if they earned less
than £11 999 per annum (pre-MI HR = 2.00, 95%
CI = 1.67 to 2.40; post-MI HR = 1.92, 95% CI = 1.61 to
2.28), or earned all their income from benefits (pre-MI
HR = 1.93, 95% CI = 1.64 to 2.26; post-MI HR = 1.91,
95% CI 1.63 to 2.25). Prior to MI, there was a difference
between participants with financial concerns of living
with or after cancer following age and sex adjustment
(HR = 1.19, 95% CI = 1.04 to 1.37); however, following
MI, the difference between the people with and without
financial concerns following age and sex adjustment was
reversed (HR = 0.83, 95% CI = 0.73 to 0.96). Following
age and sex adjustment, there was no longer a difference
in all-cause mortality for the participants who had spent
less time in full-time education, which would be expected
given the higher proportion of older people who had
remained in education for less time.
3.5 | Explanations for inequality
in survival
Adjusted Cox Proportional Hazard Models for all-cause
mortality to determine the explanations for inequality in
the survival of people with HNC are displayed in Table 3
prior to imputation and Table 4 following imputation.
3.5.1 | IMD category
Prior to MI, following adjustment by age, sex and a)
comorbidity; b) smoking status; c) alcohol consumption;
or d) tumor and treatment factors combined, there was
an attenuation in inequality by IMD Category (particu-
larly by smoking status adjustment) but inequality by
IMD Category remained strong. When the model was
adjusted by age, sex and all health and behavioral factors
including comorbidity, smoking status and alcohol con-
sumption, there was no longer an inequality in all-cause
mortality by IMD Category (Most deprived HR = 1.07,
95% CI = 0.88 to 1.31). Following MI, results were com-
parable to those of the models prior to MI for IMD
Category.
3.5.2 | Highest education level attained
Following adjustment by age, sex, and (a) comorbidity; or
(b) alcohol consumption, there was a slight attenuation
in inequality by highest education level attained but the
inequality remained strong. When the model was
adjusted by age, sex and smoking status, participants
who attained an education level up to secondary school
were no longer at a higher risk of all-cause mortality
(HR = 1.13, 95% CI 0.95 to 1.32) than those who contin-
ued to higher education or degree. Similar results were
also observed when the model was adjusted by all tumor
and treatment factors combined (HR = 1.13, 95% CI 0.97
to 1.33) but no tumor or treatment factor attenuated
TABLE 2 (Continued)
3-year survival
Age- and sex-adjusted prior to
imputation
Age- and sex-adjusted after
imputation
Variable Percent (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
£29 000 or more 83.7 (81.2, 86.0) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 70.8 (66.7, 74.5) 1.87 (1.52, 2.30) <0.001 a a
Income from benefits <0.001
All 68.4 (64.1, 72.3) 1.93 (1.64, 2.26) <0.001 1.91 (1.63, 2.25) <0.001
Some 71.8 (68.0, 75.2) 1.47 (1.26, 1.71) <0.001 1.45 (1.25, 1.69) <0.001
None 79.9 (78.2, 81.6) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 72.0 (65.4, 77.5) 1.24 (0.97, 1.58) 0.088 a a
Financial concerns 0.102
Yes 76.5 (73.9, 78.8) 1.19 (1.04, 1.37) 0.013 0.83 (0.73, 0.96) 0.011
No 76.7 (74.9, 78.5) 1.00 (Ref.) a 1.00 (Ref.) a
Unknown 71.6 (65.0, 77.3) 1.13 (0.89, 1.44) 0.301 a a
aNot applicable.
bNot imputed since data were complete so results would be the same as non-imputed model.
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inequality by highest education level attained (data not
shown). Following MI, the results were comparable to
those prior to MI.
3.5.3 | Annual household income
Following adjustment by age, sex, and (a) comorbidity;
(b) smoking status; (c) alcohol consumption; (d) health
and behavioral factors; (e) tumor and treatment factors;
or (f) all potential explanatory factors, there was a slight
attenuation in inequality by annual household income
(particularly by smoking status or all health and behav-
ioral factors); however, the inequality remained strong.
After full adjustment, the inequality by annual household
income attenuated; however, people who earned less
than £11 999 remained 34% (HR = 1.34, 95% CI = 1.01 to
1.63) more at risk of all-cause mortality than those who
earned more than £29 000. The results from the imputed
models were comparable to those prior to imputation.
3.5.4 | Income from benefits
Following adjustment by age, sex, and (a) comorbidity;
(b) smoking status; (c) alcohol consumption; (d) health
and behavioral factors; (e) tumor and treatment factors;
or (f) all potential explanatory factors, there was attenua-
tion in inequality by the proportion of income partici-
pants received from benefits; however, the inequality
remained strong. After full adjustment, the inequality by
proportion of income from benefits attenuated; however,
the participants who earned all their income from bene-
fits remained 35% (HR = 1.35, 95% CI = 1.14 to 1.60)
more at risk of all-cause mortality than those who earned
none of their income from benefits. Following MI, results
were comparable to those prior to MI.
3.5.5 | Financial concerns
Following adjustment by age, sex, and (a) comorbidity; or
(b) alcohol consumption, the inequality by financial con-
cerns attenuated; however, it remained clear. When the
model was adjusted by age, sex, and smoking status, par-
ticipants who had financial concerns were no longer at a
higher risk of all-cause mortality (HR = 1.12, 95%
CI = 0.97 to 1.28). Similar results were also observed
when the model was adjusted by age, sex, and (a) health
and behavioral factors (HR = 1.07, 95% CI = 0.93 to
1.24), or (b) tumor and treatment factors combined
(HR = 1.01, 95% CI = 0.88 to 1.17), but no tumor or treat-
ment factor attenuated the inequality by financial
concerns (data not shown). Following MI, results were
comparable to those prior to MI.
4 | DISCUSSION
Inequality in the survival of people with HNC was
observed for several measurements of SES including IMD
Category, highest education level, number of years spent
in education, annual household income, proportion of
income from benefits and financial concerns of living
with or after cancer. Participant smoking status had a
strong effect on inequality by IMD Category; however,
adjustment for age, sex, health, and behavioral factors
fully explained inequality by IMD Category. Similar
results were observed for highest education attained and
financial concerns; however, adjustment by smoking sta-
tus fully explained the inequality by these factors alone,
before and after MI. Inequality by annual household
income and proportion of income from benefits attenu-
ated following adjustment of all potential explanatory
factors; however, even after full adjustment, inequalities
remained strong before and after MI.
Previous work investigated the inequality in long-
term survival as part of the Scottish Audit of Head and
Neck Cancer (SAHNC)—a clinical cohort study of people
with HNC in Scotland diagnosed between 1999 and
2001.13 A gradient in overall, disease-specific and net sur-
vival was observed at one-, five- and 12-years, and
inequality by all-cause and disease-specific mortality was
no longer evident following adjustment of combined
patient, tumor and treatment factors. However, the
SAHNC study investigated people with HNC from Scot-
land diagnosed approximately 15 years before the
HN5000 study, from which we only included patients
from England. Survival has differed between both coun-
tries for many years,38 suggesting that people in England
have a longer life expectancy than those in Scotland. In
contrast to HN5000, the SAHNC study investigated sur-
vival using the area-based Carstairs 2001 Index39,40 which
derives deprivation through low social class, lack of car
ownership, overcrowding and male unemployment, and
therefore cannot be compared to English IMD Categories.
In addition, due to the long follow-up period, one limita-
tion of the SAHNC study was that it was recruited ahead
of the discovery of the association between HPV positiv-
ity and improved prognosis,41-43 and as a result, HPV was
not available in the SAHNC study. Moreover, the
SAHNC study did not have the advantage of the use of
individual measurements of SES.
Other UK-based studies have investigated the impact
of SES on survival of people with HNC, and inequality
was explained by people with lower SES status having
INGARFIELD ET AL. 1267
tumors of higher stage, worse comorbidities, or poorer
access to health care.10,11,44 In our study, inequality was
not explained by these factors alone, particularly for
annual household income and the proportion of income
the participants received from benefits. However, it was
clear that comorbidity attenuated inequalities by each
SES factors, but inequality was not fully explained by
comorbidity. Interestingly, inequality by IMD category
and highest education level received considerably attenu-
ated following the adjustment for smoking status. In this
study, it was not clear that adjustment by tumor stage
alone had any influence on survival for any of the SES
factors (data not shown).
There are several limitations to this study. Firstly, the
proportion of participants across the IMD groups was
even, suggesting an under-representation of the most
deprived people in this study.45 As a result, this study
may underestimate the true extent of inequality in sur-
vival of people with HNC. Secondly, participants were
given the option of taking home their baseline question-
naire to complete and return with a pre-paid envelope.
We compared those who did and did not return their
questionnaires and discovered non-returners were more
likely to be from more deprived IMD Categories
(Table S8). Previous studies have also implied that non-
respondents tend to be from backgrounds of lower SES
and have less time and capacity to participate in
research.46,47 Thirdly, after excluding a proportion of peo-
ple who did not return their questionnaire, those with
missing data for alcohol consumption and stage were at a
higher risk of all-cause mortality compared to the health-
ier groups of individuals. However, we performed MI to
overcome this issue. Finally, although we linked these
data to mortality data, we were unable to obtain informa-
tion on the cause of the participants' death. Therefore, we
were only able to investigate the inequality in survival
using all-cause mortality. However, due to the short-term
follow-up period of this study, it is likely that a high pro-
portion of deaths would be attributed to HNC, and there-
fore all-cause and disease-specific mortality results would
be unlikely to be substantially different.48
This study has several strengths. Firstly, the data are
from a large, prospective, clinical cohort study which pro-
vided a range of measurements of SES including area-
based and individual measurements. Due to the amount
of data collected via medical records and participant
questionnaires, this study allowed investigation into
many potential explanatory factors of inequality in the
survival of people with HNC via a wide range of factors
including participant characteristics, demographics,
behavioral, health, tumor and treatment factors.
We show that inequality by an area-based measure-
ment of IMD Category could be mostly explained by
smoking status, and fully explained by a combination of
age, sex, health and behavioral factors. Highest educa-
tion level attained by the study population could also be
mostly explained by smoking status, and fully explained
by a combination of age, sex, health, and behavioral fac-
tors. Full adjustment attenuated inequality by annual
household income and proportion of income from bene-
fits; however, we were unable to fully explain inequality
by these individual measurements of SES. This study
adds to the literature by exploring inequalities in the
survival of people with HNC using both area-based and
individual measurements of SES, and by investigating
the explanations for the inequalities observed. To our
knowledge, this is the first study to investigate survival
inequalities of people with HNC in such depth using
both area-based and individual measurements and
exploring the origins and explanations for the inequal-
ities observed.
5 | CONCLUSIONS
Our findings that inequalities in both household income
and the proportion of income from benefits are indepen-
dently associated with HNC survival support that inter-
ventions that address these issues (e.g., income
maximization and welfare benefit support) are included
within the wider care provided to people with HNC.
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